Clinical Trial: NCT03386942
A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Eisai Inc. |
| Information Provided By: | Eisai Inc. |
| Last Update Posted: | 2022-11-28 |
Study Overview
Brief Summary
The primary objective of this study is to evaluate the tolerability and safety profile of farletuzumab ecteribulin in participants with solid tumors.
Official Title
A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors
Conditions
Solid Tumors
Intervention / Treatment
- Drug: Farletuzumab Ecteribulin
Other Study ID Numbers
- MORAb-202-J081-101
Start Date (Actual)
2017-11-28
Primary Completion Date (Actual)
2022-10-26
Study Completion Date (Actual)
2022-10-26
Enrollment (Actual)
82
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Eisai Inc. |
| Information Provided By: | Eisai Inc. |
| Last Update Posted: | 2022-11-28 |
Study Overview
Brief Summary
The primary objective of this study is to evaluate the tolerability and safety profile of farletuzumab ecteribulin in participants with solid tumors.
Official Title
A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors
Conditions
Solid Tumors
Intervention / Treatment
- Drug: Farletuzumab Ecteribulin
Other Study ID Numbers
- MORAb-202-J081-101
Start Date (Actual)
2017-11-28
Primary Completion Date (Actual)
2022-10-26
Study Completion Date (Actual)
2022-10-26
Enrollment (Actual)
82
Study Type
Interventional
Phase
Phase 1